Xeris Biopharma Holdings, Inc. (XERS)
8.85
+0.11
(+1.26%)
USD |
NASDAQ |
Aug 25, 09:55
Xeris Biopharma Holdings Profit Margin (Quarterly) : -33.77% for June 30, 2026
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -33.77% |
| March 31, 2026 | 2.69% |
| December 31, 2025 | 12.91% |
| September 30, 2025 | 0.83% |
| June 30, 2025 | -2.70% |
| March 31, 2025 | -15.34% |
| December 31, 2024 | -8.51% |
| September 30, 2024 | -29.00% |
| June 30, 2024 | -31.22% |
| March 31, 2024 | -46.71% |
| December 31, 2023 | -30.16% |
| September 30, 2023 | -25.23% |
| June 30, 2023 | -52.20% |
| March 31, 2023 | -50.71% |
| December 31, 2022 | -39.01% |
| September 30, 2022 | -73.44% |
| June 30, 2022 | -103.5% |
| March 31, 2022 | -152.7% |
| December 31, 2021 | -237.0% |
| Date | Value |
|---|---|
| September 30, 2021 | -235.2% |
| June 30, 2021 | -308.9% |
| March 31, 2021 | -224.7% |
| December 31, 2020 | -304.8% |
| September 30, 2020 | -169.3% |
| June 30, 2020 | -1.19K% |
| March 31, 2020 | -1.63K% |
| December 31, 2019 | -1.77K% |
| September 30, 2019 | -10.49K% |
| June 30, 2019 | -10.75K% |
| March 31, 2019 | -10.19K% |
| December 31, 2018 | -2.55K% |
| September 30, 2018 | -2.54K% |
| June 30, 2018 | -1.59K% |
| March 31, 2018 | -4.53K% |
| December 31, 2017 | -1.96K% |
| September 30, 2017 | -4.43K% |
| June 30, 2017 | -926.0% |
| March 31, 2017 | -1.31K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Zevra Therapeutics, Inc. | 21.16% |
| Aclaris Therapeutics, Inc. | -1.32K% |
| ANI Pharmaceuticals, Inc. | 8.65% |
| Corcept Therapeutics, Inc. | 16.45% |
| Veru, Inc. | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Assets | -4.51% |
| Return on Invested Capital | -6.51% |
| Gross Profit Margin (Quarterly) | 83.47% |
| Operating Margin (Quarterly) | 5.62% |
| Return on Net Operating Assets | -6.50% |